New combo therapy targets hard-to-treat blood cancers in early trial
Disease control
Recruiting now
This early-stage study tests a new treatment called UB-VV111 given with rapamycin for people with relapsed or refractory large B-cell lymphoma or chronic lymphocytic leukemia. The goal is to check safety and see if the treatment can shrink tumors. About 106 adults will take part.
Phase: PHASE1 • Sponsor: Umoja Biopharma • Aim: Disease control
Last updated May 04, 2026 16:22 UTC